Search

Displaying results 5571 - 5580 of 7017 in total
  1. Drug

    MBP134

    go.drugbank.com/drugs/DB18686
    Experimental

    MBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).

  2. Drug

    Azafenidin

    go.drugbank.com/drugs/DB19031
    Investigational

    Azafenidin is under investigation in clinical trial NCT01726582 (Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")).

    Synonyms: 2-(2,4-dichloro-5-(2-propynyloxy)phenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridin-3(2h)-one, 2-(2,4-dichloro-5-prop-2-ynyloxyphenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridin-3(2h)-one
  3. Drug

    Roledumab

    go.drugbank.com/drugs/DB16317
    Investigational

    Roledumab is under investigation in clinical trial NCT02287896 (Pharmacokinetics and Safety of Roledumab in Rhd-negative Pregnant Women Carrying an Rhd-positive Foetus).

  4. Drug

    Tesnatilimab

    go.drugbank.com/drugs/DB16377
    Investigational

    Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).

  5. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency

  6. Drug

    Senicapoc

    go.drugbank.com/drugs/DB06280
    Investigational

    Senicapoc (ICA-17043) is a novel Gardos channel blocker.[A259068] It is being investigated for the treatment of sickle cell disease.

  7. Drug

    Rifalazil

    go.drugbank.com/drugs/DB04934
    Investigational

    Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.

  8. Drug

    ISIS 104838

    go.drugbank.com/drugs/DB16201
    Investigational

    ISIS 104838 is under investigation in clinical trial NCT00048321 (ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis).

  9. Drug

    PRX-OTC

    go.drugbank.com/drugs/DB17680
    Experimental

    PRX-OTC is an intracellular enzyme replacement therapy designed to replace missing or defective enzyme in patients with ornithine transcarbamylase deficiency.

  10. Drug

    Dalcinonacog alfa

    go.drugbank.com/drugs/DB17707
    Investigational

    Dalcinonacog alfa is a recombinant human factor IX (FIX) variant. It is being investigated for the treatment of hemophilia B.[A259058]